Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

You are browsing as a GUEST
Title of the item:

IFN-gamma release assays in tuberculosis management in selected high-risk populations.

Title :
IFN-gamma release assays in tuberculosis management in selected high-risk populations.
Authors :
Bocchino M; Department of Clinical and Experimental Medicine, University of Naples FEDERICO II, Monaldi Hospital, Naples, Italy. />Bellofiore B
Matarese A
Galati D
Sanduzzi A
Show more
Source :
Expert review of molecular diagnostics [Expert Rev Mol Diagn] 2009 Mar; Vol. 9 (2), pp. 165-77.
Publication Type :
Journal Article; Review
Language :
Imprint Name(s) :
Publication: 2015- : Abingdon, Oxford : Taylor & Francis
Original Publication: London : Future Drugs Ltd, 2001-
MeSH Terms :
Biological Assay/*methods
Monitoring, Physiologic/*methods
Biological Assay/standards ; Guidelines as Topic ; Humans ; Immunologic Memory/immunology ; Interferon-gamma/immunology ; Monitoring, Physiologic/standards ; Risk Factors ; T-Lymphocytes/immunology ; Tuberculosis/diagnosis ; Tuberculosis/drug therapy ; Tuberculosis/immunology ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/blood ; Tumor Necrosis Factor-alpha/immunology
Number of References :
Substance Nomenclature :
0 (Tumor Necrosis Factor-alpha)
82115-62-6 (Interferon-gamma)
Entry Date(s) :
Date Created: 20090321 Date Completed: 20090609 Latest Revision: 20090320
Update Code :
Academic Journal
Tuberculosis (TB) is the most deadly infectious disease in the world. TB control relies on passive case findings and targeted treatment of latently infected individuals at high risk of disease progression. Tuberculin skin testing (TST) is conventionally used for detection of TB infection. Recently, blood assays measuring the release of IFN-gamma by TB-specific effector memory T cells have been developed to overcome TST limitations. Overall, IFN-gamma release assays are more specific than TST, more sensitive in detecting active TB and correlate better with TB exposure in immune-competent patients, at least in low-burden settings. There are three US FDA-approved assays commercially available: the ELISpot-based assay T-SPOT.TB (Oxford Immunotech, UK) and two ELISA-based formats, QuantiFERON TB Gold (QFT) and QFT-in tube (Cellestis, Australia). Recent international guidelines and consensus statements recommend the use of IFN-gamma release assays at different levels in TB management. However, conclusive evidence-based information targeting populations at high TB risk, including HIV-infected individuals, children and patient candidates for biotherapy with TNF-alpha blockers, are lacking. The aim of this review is to focus our attention on studies addressing the performance of commercial IFN-gamma release assays in clinical management of TB infection in these highly selected settings to provide a more comprehensive picture of the actual scenario and to identify areas to be investigated further.

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.